Analyst Reco. Marinus Pharmaceuticals, Inc. Börse Stuttgart

Equities

61Y

US56854Q2003

Market Closed - Börse Stuttgart Other stock markets 15:37:13 27/06/2024 BST			5-day change	1st Jan Change
1.18 ^EUR	-4.07%		-3.15%	-87.51%

06-24	Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from S&P Pharmaceuticals Select Industry Index	CI
06-17	Sector Update: Health Care Stocks Decline Premarket Monday	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

HC Wainwright Adjusts Price Target on Marinus Pharmaceuticals to $11 From $27, Maintains Buy Rating	05-07	MT
Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating	04-17	MT
Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2	04-16	MT
RBC Downgrades Marinus Pharmaceuticals to Sector Perform From Outperform, Slashes Price Target to $3 From $24, Keeps Speculative Risk	04-16	MT
RBC Raises Price Target on Marinus Pharmaceuticals to $24 From $21, Keeps Outperform Rating	01-03	MT
Truist Securities Adjusts Price Target on Marinus Pharmaceuticals to $25 From $32, Maintains Buy Rating	11-08	MT
RBC Lifts Price Target on Marinus Pharmaceuticals to $21 From $20, Keeps Outperform Rating, Speculative Risk Qualifier	20/09/23	MT
Truist Securities Adjusts Price Target on Marinus Pharmaceuticals to $32 From $42, Maintains Buy Rating	11/08/23	MT
Ladenburg Thalmann Adjusts Price Target on Marinus Pharmaceuticals to $13 From $17, Maintains Buy Rating	11/08/23	MT
Oppenheimer Downgrades Marinus Pharmaceuticals to Perform From Outperform, Adjusts Price Target to $9 From $14	11/08/23	MT
Baird Adjusts Price Target on Marinus Pharmaceuticals to $20 From $24, Keeps Outperform Rating	11/08/23	MT
RBC Trims Price Target on Marinus Pharmaceuticals to $20 From $21, Keeps Outperform Rating, Speculative Risk Qualifier	11/08/23	MT
Truist Adjusts Price Target on Marinus Pharmaceuticals to $42 From $50, Keeps Buy Rating	12/05/23	MT
RBC Lowers Price Target on Marinus Pharmaceuticals to $21 From $22, Maintains Outperform, Speculative Risk	12/05/23	MT
Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $14 From $12, Maintains Outperform Rating	25/04/23	MT
JMP Securities Adjusts Price Target on Marinus Pharmaceuticals to $18 From $19, Maintains Market Outperform Rating	08/03/23	MT
RBC Trims Price Target on Marinus Pharmaceuticals to $22 From $23, Maintains Outperform, Speculative Risk	08/03/23	MT
SVB Securities Adjusts Price Target on Marinus Pharmaceuticals to $23 From $27, Maintains Outperform Rating	23/01/23	MT
RBC Initiates Marinus Pharmaceuticals at Outperform, Speculative Risk, Sets Price Target at $23	20/01/23	MT
Baird Lowers Price Target on Marinus Pharmaceuticals to $24 From $32, Maintains Outperform Rating	09/11/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Marinus Pharmaceuticals, Inc. Börse Stuttgart

Equities

61Y

US56854Q2003

Analyst Reco.

Filters